Livzon Pharmaceutical Group Inc 2022 SR
The report highlights Livzon Pharmaceutical Group's sustainability performance in 2022, emphasizing its "clinical value-oriented" R&D strategy. Key achievements include the emergency use approval of the Recombinant SARS-CoV-2 Fusion Protein Vaccine and the marketing of Tocilizumab Injection. The company demonstrated a strong commitment to healthcare access through equitable pricing in emerging markets and investments in rare disease treatments like Dantrolene Sodium for malignant hyperthermia. Environmentally, Livzon established a carbon neutrality target for 2055 and achieved significant reductions in greenhouse gas emission intensity. The group also maintained high standards of corporate governance, with 100% of manufacturing sites certified to ISO 14001 and ISO 45001. Socially, the company focused on workforce diversity, reporting 47.5% female employees and 25.0% women in executive management, while contributing RMB 9.98 million to charitable causes, including rural revitalization and chronic disease prevention programs.
Company: Livzon Pharmaceutical Group Inc
Sector: Health Care
Country: China
Year: 2022
Type: SR
Pages: 135
Livzon Pharmaceutical Group Inc
ESG Report
The report highlights Livzon Pharmaceutical Group's sustainability performance in 2022, emphasizing its "clinical value-oriented" R&D strategy. Key achievements include the emergency use approval of the Recombinant SARS-CoV-2 Fusion Protein Vaccine and the marketing of Tocilizumab Injection. The company demonstrated a strong commitment to healthcare access through equitable pricing in emerging markets and investments in rare disease treatments like Dantrolene Sodium for malignant hyperthermia. Environmentally, Livzon established a carbon neutrality target for 2055 and achieved significant reductions in greenhouse gas emission intensity. The group also maintained high standards of corporate governance, with 100% of manufacturing sites certified to ISO 14001 and ISO 45001. Socially, the company focused on workforce diversity, reporting 47.5% female employees and 25.0% women in executive management, while contributing RMB 9.98 million to charitable causes, including rural revitalization and chronic disease prevention programs.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees